Society for Immunotherapy of Cancer (SITC) leaders have prioritized the following areas of focus in addressing regulatory issues relating to the field of cancer immunotherapy:
SITC has forged strategic relationships with government and regulatory entities from around the world to address key regulatory issues including formal liaison relationships with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute/National Institutes of Health (NCI/NIH).
If you have partnership or policy-related questions, please contact SITC staff at SITCExecOffice@sitcancer.org.
Click here to view a complete listing of these institutions.
There is an urgent need among practicing oncologists and nurses for treatment algorithms that guide management of immunotherapy-related toxicities. Similarly, standardized templates for reporting adverse events in clinical trials are needed in order to facilitate monitoring and reporting of toxicities, an effort which is considered a high priority by the U.S. Food and Drug Administration.
To this end, SITC took the lead to convene a one-day Toxicity Management Workshop on Friday, March 31, 2017, in Washington, D.C. Click here to learn more about this event.
FDA approves first cancer treatment for any solid tumor with a specific genetic feature Do you know any commercially available kit for testing microsatellite instability in this (immunotherapy) context please? ------------------------------ Stergios ...
Don't miss Oncology Central 's FREE CME-accredited symposium on immuno-oncology. This virtual event features speakers such as James Gulley from the National Cancer Institute and Susan Slovins from Memorial Sloan Kettering Cancer Center.
Talks include ...
Did you know that through SITC Cancer Immunotherapy CONNECT you have the opportunity to ask questions of peers and colleagues from across the world?
Discuss the latest advancement in cancer immunotherapy, receive feedback on your line of work, ...
Indian FDA after clinical trials for DC immunotherapy has approved post marketing surveillance to be conducted by Delhi based research Biotech company in collaboration with oncologists. The roll out across India should start by May end. The license is ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org